Metoclopramide
 Metoclopramide injection

drug-information.ru

|Metoclopramide Metoclopramide injection

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Metoclopramide

Dosage Form: Injection

DESCRIPTION

Metoclopramide Injection is a sterile, nonpyrogenic solution. Each mL contains Metoclopramide 5 mg (present as the hydrochloride), and 8.5 mg sodium chloride in Water for Injection, USP. The pH is adjusted to 2.5 - 6.5, when necessary, with hydrochloric acid and/or sodium hydroxide. The solution is intended for intravenous or intramuscular administration.

CONTAINS NO PRESERVATIVE

Metoclopramide hydrochloride is a white or practically white, crystalline, odorless or practically odorless powder. It is very soluble in water, freely soluble in alcohol, sparingly soluble in chloroform, practically insoluble in ether. Chemically, it is 4-amino-5-chloro-N-[2-(diethylamino) ethyl]-2-methoxy benzamide monohydrochloride monohydrate. Its structural formula is as follows:

Mol. Wt.: 354.27      C14H22CIN3O2• HCl • H20

CLINICAL PHARMACOLOGY

Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of Metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs.

Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder.

In patients with gastroesophageal reflux and low LESP (lower esophageal sphincter pressure), single oral doses of Metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (the largest dose tested). The increase in LESP from a 5 mg dose lasts about 45 minutes and that of 20 mg lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg.

The antiemetic properties of Metoclopramide appear to be a result of its antagonism of central and peripheral dopamine receptors. Dopamine produces nausea and vomiting by stimulation of the medullary chemoreceptor trigger zone (CTZ), and Metoclopramide blocks stimulation of the CTZ by agents like I-dopa or apomorphine which are known to increase dopamine levels or to possess dopamine-like effects. Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.

Like the phenothiazines and related drugs, which are also dopamine antagonists, Metoclopramide produces sedation and may produce extrapyramidal reactions, although these are comparatively rare (see WARNINGS). Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin and causes a transient increase in circulating aldosterone levels, which may be associated with transient fluid retention.

The onset of pharmacological action of Metoclopramide is 1 to 3 minutes following an intravenous dose, 10 to 15 minutes following intramuscular administration, and 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours.

Pharmacokinetics

Metoclopramide is rapidly and well absorbed. Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of Metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects. Peak plasma concentrations occur at about 1 to 2 hr after a single oral dose. Similar time to peak is observed after individual doses at steady state.

In a single dose study of 12 subjects, the area under the drug concentration-time curve increases linearly with doses from 20 to 100 mg.  Peak concentrations increase linearly with dose; time to peak concentrations remains the same; whole body clearance is unchanged; and the elimination rate remains the same. The average elimination half-life in individuals with normal renal function is 5 to 6 hours. Linear kinetic processes adequately describe the absorption and elimination of Metoclopramide.

Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hours. Of the 85% eliminated in the urine, about half is present as free or conjugated Metoclopramide.

The drug is not extensively bound to plasma proteins (about 30%). The whole body volume of distribution is high (about 3.5 L/kg) which suggests extensive distribution of drug to the tissues.

Renal impairment affects the clearance of Metoclopramide. In a study with patients with varying degrees of renal impairment, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, non-renal clearance, and increase in elimination half-life. The kinetics of Metoclopramide in the presence of renal impairment remained linear however. The reduction in clearance as a result of renal impairment suggests that adjustment downward of maintenance dosage should be done to avoid drug accumulation.

Adult Pharmacokinetic Data
Parameter Value
Vd (L/kg) ~ 3.5
Plasma Protein Binding ~ 30%
t1/2 (hr) 5-6
Oral Bioavailability 80%±15.5%

In pediatric patients, the pharmacodynamics of Metoclopramide following oral and intravenous administration are highly variable and a concentration-effect relationship has not been established.

There are insufficient reliable data to conclude whether the pharmacokinetics of Metoclopramide in adults and the pediatric population are similar. Although there are insufficient data to support the efficacy of Metoclopramide in pediatric patients with symptomatic gastroesophageal reflux (GER) or cancer chemotherapy-related nausea and vomiting, its pharmacokinetics have been studied in these patient populations.

In an open-label study, six pediatric patients (age range, 3.5 weeks to 5.4 months) with GER received a Metoclopramide 0.15 mg/kg oral solution every 6 hours for 10 doses. The mean peak plasma concentration of Metoclopramide after the tenth dose was 2-fold (56.8 mcg/L) higher compared to that observed after the first dose (29 mcg/L) indicating drug accumulation with repeated dosing. After the tenth dose, the mean time to reach peak concentrations (2.2 hr), half-life (4.1 hr), clearance (0.67 L/h/kg), and volume of distribution (4.4 L/kg) of Metoclopramide were similar to those observed after the first dose. In the youngest patient (age, 3.5 weeks), Metoclopramide half-life after the first and the tenth dose (23.1 and 10.3 hr, respectively) was significantly longer compared to other infants due to reduced clearance. This may be attributed to immature hepatic and renal systems at birth.

Single intravenous doses of Metoclopramide 0.22 to 0.46 mg/kg (mean, 0.35 mg/kg) were administered over 5 minutes to 9 pediatric cancer patients receiving chemotherapy (mean age, 11.7 years; range, 7 to 14 yr) for prophylaxis of cytotoxic induced vomiting. The Metoclopramide plasma concentrations extrapolated to time zero ranged from 65 to 395 mcg/L (mean, 152 mcg/L). The mean elimination half-life, clearance, and volume of distribution of Metoclopramide were 4.4 hr (range, 1.7 to 8.3 hr), 0.56 L/h/kg (range, 0.12 to 1.20 L/h/kg), and 3.0 L/kg (range, 1.0 to 4.8 L/kg), respectively.

In another study, nine pediatric cancer patients (age range, 1 to 9 yr) received 4 to 5 intravenous infusions (over 30 minutes) of Metoclopramide at a dose of 2 mg/kg to control emesis. After the last dose, the peak serum concentrations of Metoclopramide ranged from 1060 to 5680 mcg/L. The mean elimination half life, clearance, and volume of distribution of Metoclopramide were 4.5 hr (range, 2.0 to 12.5 hr), 0.37 L/h/kg (range, 0.10 to 1.24 L/h/kg), and 1.93 L/kg (range, 0.95 to 5.50 L/kg), respectively.

Pediatric Pharmacokinetic Studies
References Dose, Route t1/2
(hr)
CI
(L/hr/kg)
Vd
(L/kg)
Cmax
(mcg/L)
a. SEM not available.
1. Bateman, DN, et al, Br J Clin Pharmac 15:557-559, 1983.
2. Ford, C. Clin Pharmac Ther 43:196, 1988.
1. 0.35 mg/kg,
IV over 5 min
4.4±0.56 0.56±0.10 3.0±0.38
(Dose/Cp0)
152±31
2. 2 mg/kg
30 min IV
Infusion 4-5 times
within 9.5 hours
4.5a 0.37a 1.93a 1060 to 5680a

INDICATIONS AND USAGE

Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide Injection is indicated for the relief of severe symptoms associated with acute and recurrent diabetic gastric stasis.

The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy: Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy.

The Prevention of Postoperative Nausea and Vomiting: Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable.

Small Bowel Intubation: Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.

Radiological Examination: Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.

CONTRAINDICATIONS

Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Metoclopramide is contraindicated in patients with pheochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phentolamine.

Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug.

Metoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

WARNINGS

Mental depression has occurred in patients with and without prior history of depression. Symptoms have ranged from mild to severe and have included suicidal ideation and suicide. Metoclopramide should be given to patients with a prior history of depression only if the expected benefits outweigh the potential risks.

Extrapyramidal symptoms, manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of Metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with Metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age are even more frequent at the higher doses used in prophylaxis of vomiting due to cancer chemotherapy. These symptoms may include involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus. Rarely, dystonic reactions may present as stridor and dyspnea, possibly due to laryngospasm. If these symptoms should occur, inject 50 mg diphenhydramine hydrochloride intramuscularly, and they usually will subside. Benztropine mesylate, 1 to 2 mg intramuscularly, may also be used to reverse these reactions.

Parkinsonian-like symptoms have occurred, more commonly within the first 6 months after beginning treatment with Metoclopramide, but occasionally after longer periods. These symptoms generally subside within 2 to 3 months following discontinuance of Metoclopramide. Patients with preexisting Parkinson’s disease should be given Metoclopramide cautiously, if at all, since such patients may experience exacerbation of parkinsonian symptoms when taking Metoclopramide.

Tardive Dyskinesia

Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with Metoclopramide. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients are likely to develop the syndrome. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the total cumulative dose.

Less commonly, the syndrome can develop after relatively brief treatment periods at low doses; in these cases, symptoms appear more likely to be reversible.

There is no known treatment for established cases of tardive dyskinesia although the syndrome may remit, partially or completely, within several weeks-to-months after Metoclopramide is withdrawn. Metoclopramide itself, however, may suppress (or partially suppress) the signs of tardive dyskinesia, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of the syndrome is unknown. Therefore, the use of Metoclopramide for the symptomatic control of tardive dyskinesia is not recommended.

Neuroleptic Malignant Syndrome (NMS)

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with Metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac arrhythmias).

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g. pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyrimidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever and primary central nervous system (CNS) pathology.

The management of NMS should include 1) immediate discontinuation of Metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, 3) treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantroline sodium have been used in treatment of NMS, but their effectiveness have not been established (see ADVERSE REACTIONS).

PRECAUTIONS

General

In one study in hypertensive patients, intravenously administered Metoclopramide was shown to release catecholamines: hence, caution should be exercised when Metoclopramide is used in patients with hypertension.

Intravenous injections of undiluted Metoclopramide should be made slowly allowing 1 to 2 minutes for 10 mg since a transient but intense feeling of anxiety and restlessness, followed by drowsiness, may occur with rapid administration.

Because Metoclopramide produces a transient increase in plasma aldosterone, certain patients, especially those with cirrhosis or congestive heart failure, may be at risk of developing fluid retention and volume overload. If this occurs at any time during Metoclopramide therapy, the drug should be discontinued.

Intravenous administration of Metoclopramide Injection diluted in a parenteral solution should be made slowly over a period of not less than 15 minutes.

Giving a promotility drug such as Metoclopramide theoretically could put increased pressure on suture lines following a gut anastomosis or closure. This possibility should be considered and weighed when deciding whether to use Metoclopramide or nasogastric suction in the prevention of postoperative nausea and vomiting.

Information For Patients

Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The ambulatory patient should be cautioned accordingly.

Drug Interactions

The effects of Metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when Metoclopramide is given with alcohol, sedatives, hypnotics, narcotics or tranquilizers.

The finding that Metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxidase inhibitors.

Absorption of drugs from the stomach may be diminished (e.g., digoxin) by Metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).

Gastroparesis (gastric stasis) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to hypoglycemia. Because the action of Metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dose or timing of dosage may require adjustment.

Carcinogenesis, Mutagenesis, Impairment of Fertility

A 77-week study was conducted in rats with oral doses up to about 40 times the maximum recommended human daily dose. Metoclopramide elevates prolactin levels and the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of Metoclopramide is contemplated in a patient with previously detected breast cancer. Although disturbances, such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of prolactin-stimulating neuroleptic drugs and Metoclopramide. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis: the available evidence is too limited to be conclusive at this time.

An Ames mutagenicity test performed on Metoclopramide was negative.

Pregnancy Category B

Reproduction studies performed in rats, mice, and rabbits by the I.V., I.M., S.C. and oral routes at maximum levels ranging from 12 to 250 times the human dose have demonstrated no impairment of fertility or significant harm to the fetus due to Metoclopramide. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

Metoclopramide is excreted in human milk. Caution should be exercised when Metoclopramide is administered to a nursing mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established except as stated to facilitate small bowel intubation (see OVERDOSAGE and DOSAGE AND ADMINISTRATION).

Care should be exercised in administering Metoclopramide to neonates since prolonged clearance may produce excessive serum concentrations (see CLINICAL PHARMACOLOGY: Pharmacokinetics). In addition, neonates have reduced levels of NADH-cytochrome b5 reductase which, in combination with the aforementioned pharmacokinetic factors, make neonates more susceptible to methemoglobinemia (see OVERDOSAGE).

The safety profile of Metoclopramide in adults cannot be extrapolated to pediatric patients. Dystonias and other extrapyramidal reactions associated with Metoclopramide are more common in the pediatric population than in adults. (See WARNINGS and ADVERSE REACTIONS: Extrapyramidal Reactions.)

Geriatric Use

Clinical studies of Metoclopramide did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.

The risk of developing parkinsonian-like side effects increases with ascending dose. Geriatric patients should receive the lowest dose of Metoclopramide that is effective. If parkinsonian-like symptoms develop in a geriatric patient receiving Metoclopramide, Metoclopramide should generally be discontinued before initiating any specific anti-parkinsonian agents (see WARNINGS and DOSAGE AND ADMINISTRATION-For the Relief of Symptomatic Gastroesophageal Reflux).

The elderly may be at greater risk for tardive dyskinesia (see WARNINGS-Tardive Dyskinesia).

Sedation has been reported in Metoclopramide users. Sedation may cause confusion and manifest as over-sedation in elderly (see CLINICAL PHARMACOLOGY, PRECAUTIONS Information for Patients and ADVERSE REACTIONS-CNS Effects).

Metoclopramide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (see DOSAGE AND ADMINISTRATION-USE IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT).

Other Special Populations: Patients with NADH-cytochrome b5 reductase deficiency are at an increased risk of developing methemoglobinemia and/or sulfhemoglobinemia when Metoclopramide is administered. In patients with G6PD deficiency who experience Metoclopramide-induced methemoglobinemia, methylene blue treatment is not recommended (see OVERDOSAGE).

ADVERSE REACTIONS

In general, the incidence of adverse reactions correlates with the dose and duration of Metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency.

CNS Effects: Restlessness, drowsiness, fatigue and lassitude may occur (see PRECAUTIONS). Insomnia, headache, confusion, dizziness or mental depression with suicidal ideation may also occur (see WARNINGS). In cancer chemotherapy patients being treated with 1 to 2 mg/kg per dose, incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without clear-cut relationship to Metoclopramide. Rarely, hallucinations have been reported.

Extrapyramidal Reactions (EPS): Acute dystonic reactions, the most common type of EPS associated with Metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of Metoclopramide per day. In cancer chemotherapy patients receiving 1 to 2 mg/kg per dose, the incidence is 2% in patients over the ages of 30 to 35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms included involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions) and rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine (see WARNINGS).

Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, mask-like faces (see WARNINGS).

Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance (see WARNINGS).

Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot-tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.

Neuroleptic Malignant Syndrome: Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability (see WARNINGS).

Endocrine Disturbances: Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia (see PRECAUTIONS). Fluid retention secondary to transient elevation of aldosterone (see CLINICAL PHARMACOLOGY).

Cardiovascular: Hypotension, hypertension, supraventricular tachycardia, bradycardia, fluid retention, acute congestive heart failure and possible AV block (see CONTRAINDICATIONS and PRECAUTIONS).

Gastrointestinal: Nausea and bowel disturbance, primarily diarrhea.

Hepatic: Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when Metoclopramide was administered with other drugs with known hepatotoxic potential.

Renal: Urinary frequency and incontinence.

Hematologic: A few cases of neutropenia, leukopenia, or agranulocytosis, generally without clear-cut relationship to Metoclopramide. Methemoglobinemia in adults and especially with overdosage in neonates (see OVERDOSAGE). Sulfhemoglobinemia in adults.

Allergic Reactions: A few cases of rash, urticaria, or bronchospasm, especially in patients with a history of asthma. Rarely, angioneurotic edema, including glossal or laryngeal edema.

Miscellaneous: Visual disturbances. Porphyria. Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.

OVERDOSAGE

Symptoms of overdosage may include drowsiness, disorientation and extrapyramidal reactions. Anticholinergic or antiparkinson drugs or antihistamines with anticholinergic properties may be helpful in controlling the extrapyramidal reactions. Symptoms are self-limiting and usually disappear within 24 hours.

Hemodialysis removes relatively little Metoclopramide, probably because of the small amount of the drug in blood relative to tissues. Similarly, continuous ambulatory peritoneal dialysis does not remove significant amounts of drug. It is unlikely that dosage would need to be adjusted to compensate for losses through dialysis. Dialysis is not likely to be an effective method of drug removal in overdose situations.

Unintentional overdose due to misadministration has been reported in infants and children with the use of Metoclopramide oral solution. While there was no consistent pattern to the reports associated with these overdoses, events included seizures, extrapyramidal reactions, and lethargy.

Methemoglobinemia has occurred in premature and full-term neonates who were given overdoses of Metoclopramide (1 to 4 mg/kg/day orally, intramuscularly or intravenously for 1 to 3 or more days). Methemoglobinemia can be reversed by the intravenous administration of methylene blue. However, methylene blue may cause hemolytic anemia in patients with G6PD deficiency, which may be fatal (see PRECAUTIONS - Other Special Populations).

DOSAGE AND ADMINISTRATION

For The Relief Of Symptoms Associated With Diabetic Gastroparesis (Diabetic Gastric Stasis): If only the earliest manifestations of diabetic gastric stasis are present,

oral administration of Metoclopramide may be initiated. However, if severe symptoms are present, therapy should begin with Metoclopramide injection (IM or IV). Doses of 10 mg may be administered slowly by the intravenous route over a 1- to 2-minute period.

Administration of Metoclopramide injection up to 10 days may be required before symptoms subside, at which time oral administration of Metoclopramide may be instituted.

For The Prevention Of Nausea And Vomiting Associated With Emetogenic Cancer Chemotherapy: For doses in excess of 10 mg, Metoclopramide Injection should be diluted in 50 mL of a parenteral solution.

The preferred parenteral solution is Sodium Chloride Injection (normal saline), which when combined with Metoclopramide Injection, can be stored frozen for up to 4 weeks. Metoclopramide Injection is degraded when admixed and frozen with Dextrose-5% in Water. Metoclopramide Injection diluted in Sodium Chloride Injection, Dextrose-5% in Water, Dextrose-5% in 0.45% Sodium Chloride, Ringer’s Injection or Lactated Ringer’s Injection may be stored up to 48 hours (without freezing) after preparation if protected from light. All dilutions may be stored unprotected from light under normal light conditions up to 24 hours after preparation.

Intravenous infusions should be made slowly over a period of not less than 15 minutes, 30 minutes before beginning cancer chemotherapy and repeated every 2 hours for two doses, then every 3 hours for three doses.

The initial two doses should be 2 mg/kg if highly emetogenic drugs such as cisplatin or dacarbazine are used alone or in combination. For less emetogenic regimes, 1 mg/kg per dose may be adequate.

If extrapyramidal symptoms should occur, inject 50 mg diphenhydramine hydrochloride intramuscularly, and EPS usually will subside.

For The Prevention of Postoperative Nausea and Vomiting: Metoclopramide Injection should be given intramuscularly near the end of surgery. The usual adult dose is 10 mg; however, doses of 20 mg may be used.

To Facilitate Small Bowel Intubation: If the tube has not passed the pylorus with conventional maneuvers in 10 minutes, a single dose (undiluted) may be administered slowly by the intravenous route over a 1- to 2- minute period. The recommended single dose is: Pediatric patients above 14 years of age and adults - 10 mg Metoclopramide base. Pediatric patients (6 to 14 years of age) - 2.5 to 5 mg Metoclopramide base; (under 6 years of age) - 0.1 mg/kg Metoclopramide base.

To Aid in Radiological Examinations: In patients where delayed gastric emptying interferes with radiological examination of the stomach and/or small intestine, a single dose may be administered slowly by the intravenous route over 1- to 2- minute period.

For dosage, see intubation above.

Use in Patients With Renal or Hepatic Impairment: Since Metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate.

See OVERDOSAGE section for information regarding dialysis.

Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal.

Admixture Compatibilities: Metoclopramide Injection is compatible for mixing and injection with the following injectable products to the extent indicated below:

Physically and Chemically Compatible up to 48 hours. Cimetidine Hydrochloride, Mannitol, Potassium Acetate, Potassium Phosphate.

Physically Compatible up to 48 hours. Ascorbic Acid, Benztropine Mesylate, Cytarabine, Dexamethasone Sodium Phosphate, Diphenhydramine Hydrochloride, Doxorubicin Hydrochloride, Heparin Sodium, Hydrocortisone Sodium Phosphate, Lidocaine Hydrochloride, Multi-Vitamin Infusion (must be refrigerated), Vitamin B Complex with Ascorbic Acid.

Physically Compatible up to 24 hours (Do not use if precipitation occurs). Clindamycin Phosphate, Cyclophosphamide, Insulin.

Conditionally Compatible (Use within one hour after mixing or may be infused directly into the same running IV line). Ampicillin Sodium, Cisplatin, Erythromycin Lactobionate, Methotrexate Sodium, Penicillin G Potassium, Tetracycline Hydrochloride.

Incompatible (Do Not Mix). Cephalothin Sodium, Chloramphenicol Sodium, Sodium Bicarbonate.

Parenteral products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

HOW SUPPLIED

Metoclopramide Injection, USP - 5 mg Metoclopramide (present as the hydrochloride) per mL - is available in the following packages:

NDC 61703-210-07       2 mL Single Dose Vial

                                       10 mg/2 mL

                                       Package of 25 Vials

NDC 61703-210-11      10 mL Single Dose Vial

                                       50 mg/10 mL

                                       Package of 25 Vials

NDC 61703-210-21      20 mL Single Dose Vial

                                       100 mg/20 mL

                                       Package of 10 Vials

NDC 61703-210-35      30 mL Single Dose Vial

                                       150 mg/30 mL

                                       Package of 1 Vial

Store at controlled room temperature between 15°- 30°C (59°- 86°F). Do not permit to freeze.

PROTECT FROM LIGHT. Store vial in carton until time of use.

CONTAINS NO PRESERVATIVE. Discard unused portion.

Manufactured for:

Mayne Pharma ( USA) Inc.

Paramus, NJ 07652

By: Mayne Pharma (PR) Inc.

Aguadilla, Puerto Rico 00604

Rev. March 2004         PI005/KC


Metoclopramide (Metoclopramide)
PRODUCT INFO
Product Code 61703-210 Dosage Form INJECTION, SOLUTION
Route Of Administration INTRAVENOUS, INTRAMUSCULAR DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Metoclopramide (Metoclopramide) Active 5 MILLIGRAM  In 1 MILLILITER
sodium chloride Inactive  
hydrochloric acid Inactive  
sodium hydroxide Inactive  
Water Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 61703-210-07 25 VIAL In 1 PACKAGE contains a VIAL, SINGLE-DOSE
1 2 MILLILITER In 1 VIAL, SINGLE-DOSE This package is contained within the PACKAGE (61703-210-07)
2 61703-210-11 25 VIAL In 1 PACKAGE contains a VIAL, SINGLE-DOSE
2 10 MILLILITER In 1 VIAL, SINGLE-DOSE This package is contained within the PACKAGE (61703-210-11)
3 61703-210-21 10 VIAL In 1 PACKAGE contains a VIAL, SINGLE-DOSE
3 20 MILLILITER In 1 VIAL, SINGLE-DOSE This package is contained within the PACKAGE (61703-210-21)
4 61703-210-35 1 VIAL In 1 PACKAGE contains a VIAL, SINGLE-DOSE
4 30 MILLILITER In 1 VIAL, SINGLE-DOSE This package is contained within the PACKAGE (61703-210-35)

Revised: 10/2006





Where can I get more information about Metoclopramide Metoclopramide injection ? We recommend to use www.Drugs.com

Typical mistypes for Metoclopramide Metoclopramide injection
netoclopramide metoclopramide injection, ketoclopramide metoclopramide injection, jetoclopramide metoclopramide injection, mwtoclopramide metoclopramide injection, mstoclopramide metoclopramide injection, mdtoclopramide metoclopramide injection, mrtoclopramide metoclopramide injection, m4toclopramide metoclopramide injection, m3toclopramide metoclopramide injection, meroclopramide metoclopramide injection, mefoclopramide metoclopramide injection, megoclopramide metoclopramide injection, meyoclopramide metoclopramide injection, me6oclopramide metoclopramide injection, me5oclopramide metoclopramide injection, meticlopramide metoclopramide injection, metkclopramide metoclopramide injection, metlclopramide metoclopramide injection, metpclopramide metoclopramide injection, met0clopramide metoclopramide injection, met9clopramide metoclopramide injection, metoxlopramide metoclopramide injection, metovlopramide metoclopramide injection, metoflopramide metoclopramide injection, metodlopramide metoclopramide injection, metockopramide metoclopramide injection, metocpopramide metoclopramide injection, metocoopramide metoclopramide injection, metoclipramide metoclopramide injection, metoclkpramide metoclopramide injection, metocllpramide metoclopramide injection, metoclppramide metoclopramide injection, metocl0pramide metoclopramide injection, metocl9pramide metoclopramide injection, metoclooramide metoclopramide injection, metoclolramide metoclopramide injection, metoclo-ramide metoclopramide injection, metoclo0ramide metoclopramide injection, metoclopeamide metoclopramide injection, metoclopdamide metoclopramide injection, metoclopfamide metoclopramide injection, metocloptamide metoclopramide injection, metoclop5amide metoclopramide injection, metoclop4amide metoclopramide injection, metocloprzmide metoclopramide injection, metocloprsmide metoclopramide injection, metocloprwmide metoclopramide injection, metocloprqmide metoclopramide injection, metoclopranide metoclopramide injection, metocloprakide metoclopramide injection, metocloprajide metoclopramide injection, metoclopramude metoclopramide injection, metoclopramjde metoclopramide injection, metoclopramkde metoclopramide injection, metoclopramode metoclopramide injection, metoclopram9de metoclopramide injection, metoclopram8de metoclopramide injection, metoclopramise metoclopramide injection, metoclopramixe metoclopramide injection, metoclopramice metoclopramide injection, metoclopramife metoclopramide injection, metoclopramire metoclopramide injection, metoclopramiee metoclopramide injection, metoclopramidw metoclopramide injection, metoclopramids metoclopramide injection, metoclopramidd metoclopramide injection, metoclopramidr metoclopramide injection, metoclopramid4 metoclopramide injection, metoclopramid3 metoclopramide injection, metoclopramide netoclopramide injection, metoclopramide ketoclopramide injection, metoclopramide jetoclopramide injection, metoclopramide mwtoclopramide injection, metoclopramide mstoclopramide injection, metoclopramide mdtoclopramide injection, metoclopramide mrtoclopramide injection, metoclopramide m4toclopramide injection, metoclopramide m3toclopramide injection, metoclopramide meroclopramide injection, metoclopramide mefoclopramide injection, metoclopramide megoclopramide injection, metoclopramide meyoclopramide injection, metoclopramide me6oclopramide injection, metoclopramide me5oclopramide injection, metoclopramide meticlopramide injection, metoclopramide metkclopramide injection, metoclopramide metlclopramide injection, metoclopramide metpclopramide injection, metoclopramide met0clopramide injection, metoclopramide met9clopramide injection, metoclopramide metoxlopramide injection, metoclopramide metovlopramide injection, metoclopramide metoflopramide injection, metoclopramide metodlopramide injection, metoclopramide metockopramide injection, metoclopramide metocpopramide injection, metoclopramide metocoopramide injection, metoclopramide metoclipramide injection, metoclopramide metoclkpramide injection, metoclopramide metocllpramide injection, metoclopramide metoclppramide injection, metoclopramide metocl0pramide injection, metoclopramide metocl9pramide injection, metoclopramide metoclooramide injection, metoclopramide metoclolramide injection, metoclopramide metoclo-ramide injection, metoclopramide metoclo0ramide injection, metoclopramide metoclopeamide injection, metoclopramide metoclopdamide injection, metoclopramide metoclopfamide injection, metoclopramide metocloptamide injection, metoclopramide metoclop5amide injection, metoclopramide metoclop4amide injection, metoclopramide metocloprzmide injection, metoclopramide metocloprsmide injection, metoclopramide metocloprwmide injection, metoclopramide metocloprqmide injection, metoclopramide metoclopranide injection, metoclopramide metocloprakide injection, metoclopramide metocloprajide injection, metoclopramide metoclopramude injection, metoclopramide metoclopramjde injection, metoclopramide metoclopramkde injection, metoclopramide metoclopramode injection, metoclopramide metoclopram9de injection, metoclopramide metoclopram8de injection, metoclopramide metoclopramise injection, metoclopramide metoclopramixe injection, metoclopramide metoclopramice injection, metoclopramide metoclopramife injection, metoclopramide metoclopramire injection, metoclopramide metoclopramiee injection, metoclopramide metoclopramidw injection, metoclopramide metoclopramids injection, metoclopramide metoclopramidd injection, metoclopramide metoclopramidr injection, metoclopramide metoclopramid4 injection, metoclopramide metoclopramid3 injection, metoclopramide metoclopramide unjection, metoclopramide metoclopramide jnjection, metoclopramide metoclopramide knjection, metoclopramide metoclopramide onjection, metoclopramide metoclopramide 9njection, metoclopramide metoclopramide 8njection, metoclopramide metoclopramide ibjection, metoclopramide metoclopramide imjection, metoclopramide metoclopramide ijjection, metoclopramide metoclopramide ihjection, metoclopramide metoclopramide inhection, metoclopramide metoclopramide innection, metoclopramide metoclopramide inmection, metoclopramide metoclopramide inkection, metoclopramide metoclopramide iniection, metoclopramide metoclopramide inuection, metoclopramide metoclopramide injwction, metoclopramide metoclopramide injsction, metoclopramide metoclopramide injdction, metoclopramide metoclopramide injrction, metoclopramide metoclopramide inj4ction, metoclopramide metoclopramide inj3ction, metoclopramide metoclopramide injextion, metoclopramide metoclopramide injevtion, metoclopramide metoclopramide injeftion, metoclopramide metoclopramide injedtion, metoclopramide metoclopramide injecrion, metoclopramide metoclopramide injecfion, metoclopramide metoclopramide injecgion, metoclopramide metoclopramide injecyion, metoclopramide metoclopramide injec6ion, metoclopramide metoclopramide injec5ion, metoclopramide metoclopramide injectuon, metoclopramide metoclopramide injectjon, metoclopramide metoclopramide injectkon, metoclopramide metoclopramide injectoon, metoclopramide metoclopramide inject9on, metoclopramide metoclopramide inject8on, metoclopramide metoclopramide injectiin, metoclopramide metoclopramide injectikn, metoclopramide metoclopramide injectiln, metoclopramide metoclopramide injectipn, metoclopramide metoclopramide injecti0n, metoclopramide metoclopramide injecti9n, metoclopramide metoclopramide injectiob, metoclopramide metoclopramide injectiom, metoclopramide metoclopramide injectioj, metoclopramide metoclopramide injectioh, etoclopramide metoclopramide injection, mtoclopramide metoclopramide injection, meoclopramide metoclopramide injection, metclopramide metoclopramide injection, metolopramide metoclopramide injection, metocopramide metoclopramide injection, metoclpramide metoclopramide injection, metocloramide metoclopramide injection, metoclopamide metoclopramide injection, metocloprmide metoclopramide injection, metoclopraide metoclopramide injection, metoclopramde metoclopramide injection, metoclopramie metoclopramide injection, metoclopramid metoclopramide injection, metoclopramide metoclopramide injection, metoclopramide metoclopramide injection, metoclopramide etoclopramide injection, metoclopramide mtoclopramide injection, metoclopramide meoclopramide injection, metoclopramide metclopramide injection, metoclopramide metolopramide injection, metoclopramide metocopramide injection, metoclopramide metoclpramide injection, metoclopramide metocloramide injection, metoclopramide metoclopamide injection, metoclopramide metocloprmide injection, metoclopramide metoclopraide injection, metoclopramide metoclopramde injection, metoclopramide metoclopramie injection, metoclopramide metoclopramid injection, metoclopramide metoclopramideinjection, metoclopramide metoclopramide njection, metoclopramide metoclopramide ijection, metoclopramide metoclopramide inection, metoclopramide metoclopramide injction, metoclopramide metoclopramide injetion, metoclopramide metoclopramide injecion, metoclopramide metoclopramide injecton, metoclopramide metoclopramide injectin, metoclopramide metoclopramide injectio, emtoclopramide metoclopramide injection, mteoclopramide metoclopramide injection, meotclopramide metoclopramide injection, metcolopramide metoclopramide injection, metolcopramide metoclopramide injection, metocolpramide metoclopramide injection, metoclporamide metoclopramide injection, metoclorpamide metoclopramide injection, metocloparmide metoclopramide injection, metocloprmaide metoclopramide injection, metoclopraimde metoclopramide injection, metoclopramdie metoclopramide injection, metoclopramied metoclopramide injection, metoclopramid e metoclopramide injection, metoclopramide metoclopramide injection, metoclopramide m etoclopramide injection, metoclopramide emtoclopramide injection, metoclopramide mteoclopramide injection, metoclopramide meotclopramide injection, metoclopramide metcolopramide injection, metoclopramide metolcopramide injection, metoclopramide metocolpramide injection, metoclopramide metoclporamide injection, metoclopramide metoclorpamide injection, metoclopramide metocloparmide injection, metoclopramide metocloprmaide injection, metoclopramide metoclopraimde injection, metoclopramide metoclopramdie injection, metoclopramide metoclopramied injection, metoclopramide metoclopramid einjection, metoclopramide metoclopramidei njection, metoclopramide metoclopramide nijection, metoclopramide metoclopramide ijnection, metoclopramide metoclopramide inejction, metoclopramide metoclopramide injcetion, metoclopramide metoclopramide injetcion, metoclopramide metoclopramide injeciton, metoclopramide metoclopramide injectoin, metoclopramide metoclopramide injectino, mmetoclopramide metoclopramide injection, meetoclopramide metoclopramide injection, mettoclopramide metoclopramide injection, metooclopramide metoclopramide injection, metocclopramide metoclopramide injection, metocllopramide metoclopramide injection, metocloopramide metoclopramide injection, metocloppramide metoclopramide injection, metocloprramide metoclopramide injection, metoclopraamide metoclopramide injection, metocloprammide metoclopramide injection, metoclopramiide metoclopramide injection, metoclopramidde metoclopramide injection, metoclopramidee metoclopramide injection, metoclopramide metoclopramide injection, metoclopramide metoclopramide injection, metoclopramide mmetoclopramide injection, metoclopramide meetoclopramide injection, metoclopramide mettoclopramide injection, metoclopramide metooclopramide injection, metoclopramide metocclopramide injection, metoclopramide metocllopramide injection, metoclopramide metocloopramide injection, metoclopramide metocloppramide injection, metoclopramide metocloprramide injection, metoclopramide metoclopraamide injection, metoclopramide metocloprammide injection, metoclopramide metoclopramiide injection, metoclopramide metoclopramidde injection, metoclopramide metoclopramidee injection, metoclopramide metoclopramide injection, metoclopramide metoclopramide iinjection, metoclopramide metoclopramide innjection, metoclopramide metoclopramide injjection, metoclopramide metoclopramide injeection, metoclopramide metoclopramide injecction, metoclopramide metoclopramide injecttion, metoclopramide metoclopramide injectiion, metoclopramide metoclopramide injectioon, metoclopramide metoclopramide injectionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved